Business Wire·Nov 9, 2026, 8:30 AM ET

Alpha Cognition Strengthens Its Board of Directors with Appointment of Caren Deardorf

ACOG

Alpha Cognition Inc. appointed Caren Deardorf to its Board of Directors effective November 9, 2026.
Deardorf joins with extensive experience in pharmaceutical commercial strategy, brand management, & corporate development.
CEO Michael McFadden stated Deardorf's expertise will support the commercial launch of ZUNVEYL® & the sublingual program.
Deardorf currently serves as Chief Business & Strategy Officer at Neutrolis, Inc., a clinical-stage biotechnology firm.
Her prior roles include Chief Commercial & Strategy Officer at Editas Medicine, Chief Commercial Officer at Magenta Therapeutics & Ohana Biosciences.
Deardorf spent 20 years at Biogen, culminating as Vice President of Global Product Development & Commercialization for the SPINRAZA® portfolio.
She led the launch of SPINRAZA®, which generated approximately $2 billion in revenue in its first two years & secured reimbursement in 30 countries.
She previously served on the board of Crinetics from March 2022 until its acquisition by Vertex Pharmaceuticals.
Deardorf is a board member of the Pan Massachusetts Challenge, a non-profit that has raised over $1.2 billion for the Dana Farber Cancer Institute.
Alpha Cognition develops therapies for neurodegenerative diseases including Alzheimer's disease & Cognitive Impairment with mild Traumatic Brain Injury.
ZUNVEYL is a patented acetylcholinesterase inhibitor with minimal gastrointestinal side effects that binds alpha-7 neuronal nicotinic receptors.
The company is also developing ALPHA-1062 in combination with memantine for moderate to severe Alzheimer's dementia & as an intranasal formulation for Cognitive Impairment with mTBI.
The release includes standard forward-looking statements regarding business strategy, clinical trials, regulatory approvals, & patent risks.